文献速递血液净化与透析

腹膜透析联合每周一次血液透析与每周三次血液透析的结局相当:一项前瞻性队列研究

Comparable outcomes between a combination of peritoneal dialysis with once-weekly haemodialysis and thrice-weekly haemodialysis: a prospective cohort study.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

该前瞻性队列研究利用日本透析治疗学会肾脏数据登记系统,纳入2011至2018年从腹膜透析转为腹膜透析联合每周一次血液透析或每周三次血液透析的患者。主要分析显示两组全因、心血管、心力衰竭相关及感染相关死亡率无显著差异,部分敏感性分析中联合治疗组全因或感染相关死亡率显著更低。作者认为联合治疗可提供灵活生活方式,可能是一个好选择。

要点

  • 联合治疗组与每周三次血透组全因死亡率无显著差异(HR 0.95,95%CI 0.78-1.16)。
  • 心血管、心衰相关及感染相关死亡率在两组间均无显著差异。
  • 部分敏感性分析中联合治疗与更低全因或感染相关死亡率相关。

核心结论

  • 腹膜透析联合每周一次血液透析与每周三次血液透析相比,死亡率相似或可能更低。
  • 作者认为考虑到灵活的生活方式,联合治疗可能是一个好选择。

研究设计与样本

  • 前瞻性队列研究,使用日本透析治疗学会肾脏数据登记系统。
  • 纳入2011年至2018年从腹膜透析转为腹膜透析联合每周一次血液透析(1001例)或每周三次血液透析(2031例)的患者。
  • 暴露为腹膜透析联合每周一次血液透析,对照为每周三次血液透析,结局为全因或特定原因死亡时间,采用Cox回归分析。
  • 敏感性分析包括倾向性评分匹配、共享frailty模型、逆概率加权、倾向性评分调整、分层、竞争风险回归及on-treatment分析。

主要发现

  • 中位随访3.5年期间共575例死亡。
  • 全因死亡率两组无显著差异(HR 0.95,95%CI 0.78-1.16)。
  • 心血管死亡率两组无显著差异(HR 1.26,95%CI 0.92-1.72)。
  • 充血性心力衰竭相关死亡率两组无显著差异(HR 1.24,95%CI 0.77-1.99)。
  • 感染相关死亡率两组无显著差异(HR 0.89,95%CI 0.57-1.39)。

临床怎么用

  • 作者认为腹膜透析联合每周一次血液透析可提供灵活的生活方式,可能是一个好选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcomes of a combination of peritoneal dialysis (PD) and once-weekly haemodialysis (PD + HD) have not been extensively studied. METHODS: This prospective cohort study using the Japanese Society for Dialysis Therapy Renal Data Registry included those who transitioned from PD to PD + HD therapy or thrice-weekly HD from 2011 to 2018. Exposure was PD + HD therapy compared with thrice-weekly HD. The outcome was time to all-cause or cause-specific death. Associations between PD + HD therapy and outcomes were examined by Cox regression. Sensitivity analyses were performed by propensity score (PS) matching, PS matching with a shared frailty model in which dialysis facilities were treated as a random effect, inverse probability weighting (IPW), PS adjustment, PS stratification, competing risk regression and on-treatment analyses in which data were censored at the transition to thrice-weekly HD for those on PD + HD therapy. RESULTS: During the study period, 1001 subjects transitioned to PD + HD therapy and 2031 to thrice-weekly HD. During a median follow-up of 3.5 years, 575 subjects died. All-cause, cardiovascular, congestive heart failure-related or infection-related mortality were not significantly different between those on PD + HD and those on thrice-weekly HD [hazard ratio 0.95 (95% confidence interval 0.78-1.16), 1.26 (0.92-1.72), 1.24 (0.77-1.99) and 0.89 (0.57-1.39), respectively]. Sensitivity analyses yielded similar results except that PD + HD therapy was associated with significantly lower all-cause mortality by PS adjustment and PS matching with the shared frailty model and lower infection-related mortality by PS adjustment and IPW. CONCLUSIONS: PD + HD therapy was associated with similar or potentially lower mortality compared with thrice-weekly HD. Considering a flexible lifestyle, PD + HD therapy could be a great option.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Murashima M, Hamano T, Abe M, et al. Comparable outcomes between a combination of peritoneal dialysis with once-weekly haemodialysis and thrice-weekly haemodialysis: a prospective cohort study. Nephrol Dial Transplant. 2023. PMID: 36702533. doi:10.1093/ndt/gfad019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。